Immunogen (IMGN) 6 May 222022 Q1 Earnings call transcript

Good morning and welcome to ImmunoGen's First Quarter 2022 Financial and Operating Results Conference Call. Today's conference is being recorded. At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications. Please go ahead.

Good morning, and thank you for joining today's call. a progress that financial and issued of a results. we recent our first today, press includes release summary Earlier quarter XXXX be at immunogen.com. This this & a and section found can Media website press Investors under our recording of the release call of Medical are and Chief Susan CFO. Kristen me Altschuller, Berkenblit, today and Anna Chief Enyedy, our Mark With Harrington-Smith, President our our CEO; our Officer; Officer; Commercial

accomplishments events. for and During the our today's review call, results anticipated we QX highlight recent upcoming will financial business,

annual We forward-looking statements current subject differ and making filings, Form issued other the Mark. with will over in in and our to expectations release are and which that, report results call on press consult actual this and Factors uncertainties, our the I'll be risks on based statements most morning Risk our immunogen.com. SEC XX-K to at section outlined and beliefs. available may are sec.gov of These the And turn please recent our in materially, risks our

morning, joining SORAYA you continued XXXX. Building make late raise excellent today. for year, to last us thank and capital strong progress data the in on Good and we've

to at ovarian priority and achieved end: folate-receptor for patients approval Our alpha for of SGO of to results accelerated we FDA presentation BLA X the potential pivotal and mirv in trial high, the positive monotherapy is top critical SORAYA gain milestones that approval. platinum-resistant cancer, recently with to our the from submission

and with further studies monotherapy, the on To release enrollment in enrollment commercial trial initiated SORAYA. confirmatory and so we've cohorts preparations pivek interim starting a since line the continued in in As becoming our accelerated top is III futility accrued global to our these only following study, the the This of expect the on MIRASOL MIRASOL AML of a our provide line and will timing analysis with from more with and mirv, our earlier-stage reach not we anticipation analysis. and pivotal a from company, an prespecified quarter requisite both pivek a Anna is of in IMGNXXX. label integrated start and venetoclax we fully towards event-driven events expand BPDCN, of moment. Phase IMGCXXX expanded the study recent also programs, with patients progressed in progress oncology year, reforecast factor XXXX. in of accelerated team in for of studies now relapsed expansion results report combining upon line PICCOLO the frontline Based azacitidine our and patients mirv enrollment of launch generated mirv MIRASOL top II our Phase conjunction and confirmatory and CADENZA approval, this in of points, color the year number expansion the early PFS top data fourth MIRASOL, this in in goal the

second before CADENZA pivotal we data nicely, frontline is BPDCN expect pivotal efficacy program, our from and preliminary study year-end. Our progressing pivek, in

pivek, evaluating which enrollment is our rapidly. AML in in In Phase cohorts and expansion relapsed azacitidine patients, frontline and addition, patient ongoing accruing venetoclax Ib/II both are

We year. both this ASH expect share at to from cohorts later data

dose MacroGenics. pipeline, year-end anticipate which data Phase our sharing rest the we ADAMX from of we ADC, our the at are initial targeting I IMGCXXX, with Looking of before trial first-in-class escalation codeveloping

was evaluation accepted Cancer recently a Molecular publication addition, available online. manuscript at soon and will describing of the IMGCXXX for In preclinical Therapeutics be

catalysts color I date regarding over CMC value positioned and midyear. remainder IMGNXXX our that, expect of We also to With on request provide the study turn the Phase the information to program. year. the our the to well meaningful as call FDA progress additional ahead, mirvetuximab made we initiate believe from by I'll we With addressing Anna through clinical we create meaningful are of significant move Anna? and to to the study progress

thrilled to the Annual then, engage the cancer session Since We present with and we these in have Mark. stakeholders enthusiasm March. Meeting Thanks, mirvetuximab the is the plenary continued have the results broader trial Dr. program were ovarian at from SGO for in pivotal a data and to high. the SORAYA across community

study all had options enrolled arm stage rates and Treatment reminder, IV a prior and endpoint a patients disease, single PARP a bevacizumab. received of occur which XX.X% cancer. response. population. produces of overall inhibitor. duration The SORAYA prior of consists XX% single-agent cancer platinum-resistant had heavily and is with patients, had folate-receptor an XX% in As pretreated of chemotherapy, SORAYA therapies ovarian included a of III Phase was whom evaluating high, which alpha population received of had SORAYA responses, XX% X mirvetuximab limited rarely complete for platinum-resistant X response ovarian this response in prior rate low XXX primary

we program color median we managed safety data, SGO, X.X These X.X our are of study, response, therapy is that over The the reversible inhibitor was frequent from high like the with median if blurred in SORAYA in that also in PARP FORWARD we question consistent of was profile ASCO, a eye foundational were provide on with and performed? grade, dry were is that by PFS use. bevacizumab, X and small the including these showed the control at regardless mirvetuximab number population priors predominantly in control FORWARD modifications. key chemotherapy all SORAYA. prior At supportive nevertheless, forward treated was But median all in these SORAYA SORAYA. and by consistent of need to I patients the consistent keratopathy, based progression-free I SGO, months. equivalent and more I PFS secondary this of safety with and and vision, endpoint, bev as Remember seen pretreated the data GI durability PSX+, the efficacy to X integrated most impact presenting of Reviewing the in with observed platinum-resistant prior with a patients or FORWARD clinical or to investigator adverse how with with what alpha and data chemotherapy of in by arose worse of in the rate X.X due disclosed dose of data, look unmet as progression-free a At arm the with X:X months survival, The showed numbers, arm XXX to heavily meaningfulness low needed. PFS randomization. post-hoc underscores XX plan the median curve, survival One to Phase broader SORAYA, ocular the prior months. updated of we generally SORAYA similar events higher population population lines representing mirvetuximab Importantly, pretreated fatigue. CA-XXX control and is FR which duration all nausea, response efficacy and and measures mirv PFS, we patients saw common events, modifications, with characterized I median is this and the especially months dose this of patients that X.X analyses under on patient

chemotherapy in heavily a with supports less population it improvement PFS In PFS pretreated a a show median MIRASOL. meaningful mirvetuximab will clinically our over addition, that in in belief longer

we as study IDMC analysis, continue recommended pleased are Moving to report have recently the And MIRASOL. to we completed modification. without mentioned, Mark the an and interim

a top rate line increased data include are MIRASOL of line MIRASOL Considering and to top assessed of event our guidance interim the completion in disclosure fourth results, the Following enrollment and early we the SORAYA conjunction with significantly. now date enrollment updating projected the the acceleration quarter XXXX. having continued in PFS in analysis, primary

the based data. to potential for on been the SORAYA monotherapy line While we accelerated adjusted, year top expect for data approval mirvetuximab this timeline MIRASOL's has continue

platinum-sensitive support to folate-receptor label continuing mirvetuximab ovarian in need an to of of we're for the study are in population an mirvetuximab rest I Turning PICCOLO, nonplatinum high single-arm increasing antitumor effective our alpha cancer quite later intended to enroll option promising. platinum-sensitive activity we our this with in lines the expansion. and is monotherapy, patients Phase believe disease, There program, of recurrent

strategy combination choice mirvetuximab also as is agent the Our position to of advancing.

GLORIOSA doublet second-line proximity doublet of GLORIOSA gain cancer expect ovarian mirvetuximab. enroll the modest by alpha the improvement midyear. months monotherapy the addition recurrent bevacizumab of initiate approval to versus mirvetuximab maintenance of PFS in first evaluate platinum-sensitive the maintenance in the with in expect a underway, and will We close initial study to a listing setting. mirvetuximab to plus is Phase bevacizumab III of bevacizumab patient The the to patients platinum plus work this high compendia provides maintenance to X X to just alone Furthermore, in folate-receptor benefit of setting. bevacizumab for we

data promising the observed low, mirvetuximab's study So mirvetuximab over folate-receptor to followed Kristen? high we to is the we setting. recurrent excited the mirvetuximab for in we generated plus out disease, plan for carboplatin by activity this Phase on bevacizumab XXX mirvetuximab escalation potential treatment initiate XXX. trial upon have improve to Based mirvetuximab platinum-sensitive dose on in Trial plus is our in by preparations. This XXX or turn I now Rounding ovarian the cover plus this commercial Kristen based mirvetuximab inform program in registration that, alpha, platinum-sensitive this to Phase our single-arm with I'll setting. And path medium of quarter a to approximately II patients to continuation carboplatin, cancer. with in are call

this later built following of In key Thanks, accelerated including year Operations we've FDA, Head commercial our approval of Access, to hires, potential team market Sales. Strategy and our and mirvetuximab anticipation by leadership with some Anna. bringing Market

and working imperatives. patients. in we efforts, mirvetuximab in-house alpha guidance of deliver a ovarian team. positive testing reminder, selected and mirvetuximab experiences of quickly talent, key we both and we The has physician patient for and barriers education we in focused folate-receptor limiting experience. address through launch the focused In standards of continue with attracting close on and to our supporting testing for only partnership potential Not of treatment adoption expression, start the will cancer, the onboarded have identify expectations intense seamless for on approval, That of addition best-in-class seeking affairs. colleagues supporting redefining also have upon as we made platinum-resistant launch broad alpha are those And receptor awareness for to establishing be moved and outcomes payer and purposeful tailored been in while and educational agency reimbursement patient folate early our progress for a with testing requirements and our medical means to are and commercial access patient XXXX centralized ensuring also successful a for and and to record, for management have positive importance to are on

optimize and assessment our customer-facing a drive commercial and roles determine to we've relevant go-to-market and initiated identify the field to demand, addition, providers prioritize team. In accounts necessary

front, On shipment access shortly the actively after patient market setup ready customers approval. platform distribution with support we've partners and to we are have channel services working our for of initiated our mirvetuximab to

high-impact with successful the With to we in and turn are mirvetuximab bringing focus agile we believe in Susan that, high-priority, So over initiatives to experienced I well on the to an launch, look soravtansine forward place, and positioned cover to will our for a Susan? we need. call team patients financials.

Kristen. Thanks,

of include we quarter million compared fees, in were recognition of and revenue $XX.X first came quarter $XX.X the which received first first $XX XXXX in substantially million revenues. quarter The under balance royalty XXXX, the company's million $XX.X $XX.X first the the the $XX.X agreement of cash million in with R&D noncash of expenses and $X.X $X.X the came of administrative with in sheet. quarter and the quarter Medicine, $XXX.X of million a from of expenses company's of million which with generated selling, $XX.X previously Operating upfront million general quarter license million Huadong agreement compared million license in fees We and XXXX. and first remainder million comprised of $XX.X from expenses For under of the with fee with compared ended Lilly. with XXXX million first $XX.X on in received million of the milestone collaboration

Our for remains unchanged. XXXX financial guidance

to revenues between operating and and million. expenses between We million between and cash and million $XXX million, at $XXX year-end million be and cash equivalents $XX expect $XX million $XXX $XXX

timing in approval from mirvetuximab, product potential guidance does not for yet revenue range mirvetuximab. the sales Given of potential include

With product revenues combined the our call with into that will for and cash, expect XXXX. fund open questions. collaboration comfortably We anticipated operations that, we'll current

Cannacord. [Operator is Instructions] Our question from first Newman John from

SORAYA mentioned the picked following you So this up the to that for MIRASOL the remains same. confirm data year, planned of target enrollment just for wanted enrollment MIRASOL that presentation

this the after the the this use and were for that you doctors Avastin, You paradigm listing compendia where do wondering of certainly in also mentioned rituximab be treatment if the plus mirvetuximab approval, might to anticipate is think initial that I'm used? combination combination, you were combination case what

Thanks, John.

MIRASOL XXX from remains line target SORAYA same So increase our patients. top for late for data presented MIRASOL did and at kept the the XXX year we at have last enrollment target patients. after so Enrollment we

the we receiving to For in anticipate plus mirvetuximab approval. Avastin proximity our initial listing compendia combination, close

turn be combination where might over it to discuss that And so I'll Kristen to used. Harrington-Smith

Sure.

when So any platinum-resistant ovarian plus line, or of receive combo bevacizumab. we that regimen Avastin fourth-plus, more at of XX% chemotherapy patients the fourth, with kind we cancer well dynamics, a look over market second, in see third, than any

in we across will So anticipate it already those used that combination used where lines. it's be

Our with comes from Schmidt next question Michael Guggenheim.

I additional share analysis? trial. don't how patients what role perhaps MIRASOL MIRASOL, that many the perhaps was if have and event? wondering obviously on you if on were focused that's I in overlapping you perhaps information triggered that around assessed patients skew interim -- enrollment on what parameters that a Avastin-naive the the overall if then that just curious Anna, PFS SORAYA, in the just cadence at this analysis? MIRASOL and play this which dynamics the of the a patients And of may Avastin SORAYA trial could early I and with sites were the enrollment whether question whether may pretreated I'm in study towards had know second wondering you was any just

Yes. Thank Michael. you,

we a MIRASOL, had analysis prespecified interim for futility. for So

allow for primary ready an to Just we shape will, protocol-specified the had it's dry from in point. the run, that a analysis if when end done so do FORWARD to like we know really perspective you for in I, final operational we're good we're

triggered PFS was we at it XXX had time So the events.

IDMC in is This so and exactly data trending without PFS that's the in to the to continue long recommended as right the efficacy as us was And what terms planned, study direction. study modification. to of as continue

Turning dynamics. second enrollment regarding to question your

that You participated sites have in SORAYA both are MIRASOL. correct that we in have are participating do and

was so patients Avastin Avastin and Avastin pretreated SORAYA and allows limited And both naive. pretreated to MIRASOL the

MIRASOL, in sites rather extended around of extent demographics with that what MIRASOL, Avastin percent the can -- or the the patients behaving in as prior tell Given I globe enrolled patients the of is looking tracking participating the the you of are patients basically expected.

year. forward to sharing And the data so from we next look MIRASOL early data

this Okay. then I follow-up And patients unrelated the the and the of I be where for you filing? of us hurdle data had could the line of just that wondering on study is Great. study on part number an was BPDCN, you in CADENZA later noted in the will and remind just if that top year track

Yes.

And study setting. up efficacy rule really the around it's received feasible the we in indication, So from toward XX%. you what's patients. us therapy a that designation guided generated ultra-rare an may is XX out recall cohort CRCRC and a a relapsed/refractory of data the rate BPDCN breakthrough we to in frontline in to design FDA And pivotal for hurdle

less early efficacy so to the And patients. have XX do stop we trial than opportunity for the with

And so track later data we're have this to on year.

question next Markets. with comes from Our BMO Darout Etzer Capital

A couple for me.

of the any the The PFS reforecast of maybe guess first of PFS I post it second and PFS underlying on guess, you the more and and this introductory could you've back guess, recent sort submitting is X.X-month the I of help in imply you factor presented back if could would the or for the FDA. I or that you sort differences remarks mentioned assumptions? pushes go MIRASOL it something sort chemo patients acceleration trial. in events, analysis whether be not Or of one, us in a Avastin does the understand, And the just question, the pretreated if to is enrollment? to And to the of in

Thanks, Etzer.

when not reforecasting disentangle and pulls our factor endpoint. having regarding of on in not uptick in X. bit events And in of geopolitical the in an China, Russia a we to and events. that is the an for how and see will assumptions -- designed of of enrollment is have involved timing pushes in also did enrollment, certainly and terms your Shanghai. progression-free say question terms But So regarding based been rate going performing, the been and COVID in thinking on with those in and of changed really we of the the PFS study Ukraine the is after it's we surges study. possible what's the the accelerated lockdowns survival on Beijing terms has both the based PFS And MIRASOL. And it rate we shared data. I yes, first offset a enrollment SORAYA event-driven

next forward is So we multifactorial, top sharing line to year. data it look and early

Turning a to of arm the not But FORWARD really, your And to the on data in eligible subset, our regarding peer-reviewed perspective, we manner. those it in published are survival question that these data control need have you available second I progression-free the certainly, will, SORAYA from patients. if unmet FDA. are X.X-month just in the the highlights sets chemotherapy

rescored need. performed is caution blown. X.X were read analysis the the with I do months just analysis. out. using large pretreated Avastin. the the we PFS X.X an The exploratory unmet look SORAYA, in this a to the stratification folks cancer, studies none had prior And platinum-resistant we under to all have extremely It's that the or studies months, FORWARD population, I we of have we patients And uniformly unmet need. of As after for received an that all prior factors that them know high of need ovarian is highlighting these once that PSX+, chemotherapy through PSX+ the whom patients

SORAYA it's demonstrated biological have say chemotherapy not they does I is patients, options. well And in need work would that. consistent so from entirely the perspective all better these a And that data

Boris question Cowen. comes with from next Peaker Our

Can you guys hear me?

Can now.

Awesome.

a you that So was any kind ratio? threshold follow curious, can there I completed. more what to PFS some just the just little a interim on maybe up or a specific rules of recently analysis I'm the kind on of wanted comment if were MIRASOL stopping hazard

the the demonstrate chemotherapy. mirvetuximab trending hazard over in just for direction PFS to Boris, ratio Yes, needed right

low, the that Trial alpha of And of you're And patients patients I I'm also you expressing Got some other objective including of expressing just platinum-sensitive of in what's patients, it. these want on lower some curious in just folate-receptor and to XXX enrolling high the the exploring studies? your are medium any these patients? lower

So we did folate with carbaplatin when with the benefit who high really patients with expression. mirvetuximab mirvetuximab early receptor combining a Avastin, in development, now include range combination that we know did alpha broad our patients most monotherapy. it's Boris, study of from We

really We showing saw mirvetuximab plus nicely with also XX set both have those that with patients FR the mediums benefit plus levels nice very data highs this for was escalation carboplatin. expression combinations, that It a with know also, doublet. dose and we due the just And bevacizumab alpha in well mirvetuximab particular, mirvetuximab patients. small published from from also Phase carboplatin really of I and lower extremely medium. the responses plus in we including data And

lean should and combination the the mirvetuximab carboplatin of a The so benefit FR expanding higher patients of alpha FR levels a patients activity that more a a more look is lean hypothesis on the the will and alpha doublet activity Boris, in with FR of will And range understanding larger really alpha little lower expression the Trial patients broad with expression with forward that expression. XXX. on little population we of this our to here, in levels

Hsieh from William comes Andy question next Blair. Our with

Great.

curious additional events discussions appreciate I'm you ever PFS terms came of on an XXX we're information if the events housekeeping. of wondering there. trigger the FDA, has AdCom enrollment? the just are in discussion? the the just I'm with required many your remind So curious us to could previous the to of front, And of in up the target XXX And also subject PFS mirv, just analysis primary on regulatory out during having moving how

forth dosing. curious kilogram I'm the You that lastly, the mentioned process forward for FDA? And be micrograms the about certain then kind we kind an and the after active? just of per about Is a after should that of or there you time, CMC, a as the about Is IND XX it like back of submit there data think period examining? with becomes where you'll it

Andy. I'll take right, Great. X. All all

primary the triggered X the that PFS first progression-free XXX have is we be the MIRASOL, is events. when So analysis and survival, will for endpoint

not are regarding March, to requests. months ADCOM submitted of speculate second the needed, we that you at can with will And FDA should would coming your recall we responding and will BLA drug in be engaged our prepared the an we've the we to FDA tell question ADCOM, of given or the what For require outcome. on activity FDA end actively for that we SORAYA can't understand and certainly, whether an may the profile that expect information seen an I safety be you I but say,

your lifted then an to initial going make and enrolling and comment Mark. is process quite turn kilogram. to this later we to in cohorts for micrograms question From pivek, last for for with the start it is say, we're relapsed then CMC question, have we'll Phase expansion X.XXX I the triplet combination them opened I'll year. actually with II those. enrollment and per pivek clinical And providing the FDA, interacting when cohort. -- venetoclax both we for must to in AML yes, schedule and as And to data And as well it already with relapsed/refractory milligrams we XX dosing kilogram the patients hold will then of have azacitidine per over frontline anticipate the or the and recommended Going be third your in AML both

Nothing to add.

Our next Jefferies. Shi question comes from with Kelly

the ECOG chemo ECOG will And versus in the treatment performance patient trial? enrollment? in outcome arm you color could the timing enrollment, also, more First, has the mirv the your status and split do X view data then the to for FORWARD could think both regarding at And trial? phase we complete And trial you MIRASOL next for consistent the share the in readout? And how select efficacy the be MIRASOL certain influence regarding bar X would types previous first with for XXX, study? Item of expect IMGCXXX, inpatient to data lastly I tumor what many the

Sure.

we So MIRASOL being summer. anticipate this fully enrolled

second your And with on patients status ECOG to predictor Moving an regarding ECOG how do, ECOG focus important will question or is for performance an status. performance of patients performance therapy. X how they'll X. we status tolerate enrolling

So either may living. and daily patients well activities or bit of feel to they little able perform work perfectly their of tired, all a certainly be but

of enrolling in variety both your And ECOG lastly, therapies seen And our around in are on similar XXX. consistent that arms. able then gastroesophageal solid targeted so to will I. and ADC. the a breast we be patients is expect This is And with colorectal anticipate expressed to both subsets in what ADAMX for MIRASOL pancreatic patients, of triple-negative cancer lung, tolerate been of been what FORWARD population even and we've ADAMX this the these cancer. question has including we tumors,

dose mini Phase -- pursue which escalation, then types us type dose a will and that in the in we recommended package year will to identifying once cohorts we this potentially have the in guide initially expansion schedule, approval. sharing cohorts share. sufficient tumor data and in focused all look And accelerated on we and or formal we're data I so to can forward tumor regarding data and interpret expansion support we point, At this

Our JPMorgan. next with question comes from Jessica Fye

submission? with when priority you to to like by for of middle you to then getting from And through enrollment when year, that initiate filing mirvetuximab you you achieve trial? this me label? you particularly you've it would you answer can to on SORAYA the in received review about data expected seeing being that the probability GLORIOSA should handicap you lastly, the if Avastin, SORAYA the data given hear walk just prior that First, question, expect with submitted, respect you're potentially running on do the think around label hope we can how remind Second, seems that based of broad of

Yes.

anticipate from the filing we of the this their by end regarding back review. So hearing granting of month acceptance and of FDA priority

label. data label, in the have the data response broad the with bit I of with you is could pretreated for we what less see point actually of in given the out higher strength Regarding rate plus mirvetuximab that monotherapy into terms the heavily naive than SORAYA, Avastin population. chemo a gone this a from a Avastin

know these excited better And going in about it's really based a data, population, impressive bev mirvetuximab, we're the so we bev-naive pretreated to even population. and that pretreated heavily on in activity this look

terms we of this study, getting to forward we in really it excited why really, we're then running have in that is how label. odds on would and midyear. and So go. And about hesitant look the with GLORIOSA, gone thirdly, broad this I would be to up put any

and this our think we we of we we'll things guidance. then I Jess, are get think activated of going, study. when from are to running, update got share up and will early, we a sense it's little bit how have a sites But data we've once course,

Catanzaro [Operator Instructions] next from Piper Our question comes with Sandler. Joe

So think were track maybe not I. from having first right one, been on enrollment dynamics more your I call back were distributed enrollment you FORWARD you last despite than said because completed XQ readout February, evenly MIRASOL the in on

on an lines? time now I enrollment So I is then follow-up. why understand to little And better a impact have having want pace a on just

COVID events of Yes, the Russia. trial. sure. all would Well, in prior was in February And recall, the we countries a may of Beijing and And the to the surge those Ukraine you Shanghai. it understood in extent of had lockdowns was they anticipated portion geopolitical X really before we and enroll also resulting

anticipated. is unfortunately, had as not that, out we so And handing quite

So that than one reproject the interim more is it we now is the data rate. driver allowed analysis the now us of February. drivers from the clear to that's in that event have was the that other But

multifactorial. really it's So

guess guys much behave I just that understanding other if to SORAYA, And prior exactly mirv's to experience helpful. consider That's we how on and it I you multifactorial, it data. seemed in I could Okay. FORWARD pretty if based it's add, expected

reason I wondering could, your in fact, outperforming there? any any why could thoughts different and there is So maybe, speculation, mirv if you have know pure any MIRASOL but in from way, expectations? be be that's SORAYA

we're you to possibility. data that's from that's pure And really with speculation. because certainly I MIRASOL think the Agree see a excited

Jonathan Our SVB next comes Securities. question from Chang with

prior impact, PARP what question, use have in arm anticipate you performance MIRASOL? would if First any, chemo the would on

that The it reason with or the has for is mirvetuximab solidly you have that very of question. for set answered thank was an activity not. we prior mirvetuximab use data SORAYA PARP question that Jonathan, that really nice that showing outstanding asking you're regardless

the with have support damaging to to damage. the -- say that. to or And a is stratum arm. is randomized of the in I study, a percentage I inhibitors that seen patients activity prior with that repair mechanistically, the like inhibitor paclitaxel, the assigned potential of chemotherapy. X higher I is that Doxil PARP MIRASOL may be is myself PARP than think and I decrease inhibitors don't with for to to going the prior in agent, is worse. Doxil there there impact PARP FORWARD and point any DNA interfere data were But reason there Doxil weekly patients will of Your DNA perform that have the speculated I, oil how topotecan chemotherapies, carboplatin

chemotherapy. The this data going inhibitor think and is would I studies early speculating. that prior of other the increase inhibitor is for a was is activity against just Doxil of head-to-head randomized chemotherapy to don't versus negative. I But study was little me PARP PARP say, one certainly kernel,

So chemotherapy anticipated or arm either potentially think I do will as worse. the control

at ahead you it. as AML? benchmarks data combination And the the appropriate ASH, relapsed/refractory success of question, second just Got pivekimab for frontline do what see and in

we’re So in triplet bar think there. has And I VEN+AZA is And the frontline data. AML, tracking doublet the high. admittedly also the the Magrolimab closely bar set

translate CR, post CRI rate would would be at. those the bars less think something So thinking a XX% setting a that In But works. a are benefit setting, setting relapsed/refractory that the else I the it’s especially clear, could exciting of for the little meaningful we’re we really in patients. be in into relapsed VEN where nothing looking that

question with Canaccord. John Newman a next is Our follow-up from

investors you agreement comment if retrospective help data subset the if So did those skeptical -- But you, just on I I could overall in know I interpretation I of the which is just SORAYA probably of inform the in think and the are you retrospective FORWARD I just analyses, that of study? about of so. actual sometimes could think ahead wondered curious that have between may rightly PFS months don't that if you numbers it from Because but that? talk I overlap. you the front analysis X.X

Yes.

consistency efficacy think, I is mirvetuximab remarkable for development. John, throughout to So the referring of you're what

above And so really of median XX%, median quite we XX response months, PFS we that SORAYA-like, SORAYA accurately. are rate had the a had study X.X that had foundational And of X.X we a response patients months. basically who duration in of a we replicated

mirvetuximab for mirvetuximab FORWARD FORWARD with the high Dr. MIRASOL-like I X.X. patients show post-hoc saw alpha for where treatment should for looking effect did we hazard by from review nice chemotherapy. data the Moore around FR ratio presentation the that independent by investigator both exploratory blinded analysis replicate I and anticipate ESMO a we XXXX folks a point population very MIRASOL similarly, the And over I at chemotherapy, versus for so study of would And to in study. the

a And so we've more of conservatively. designed so around hazard MIRASOL X.X, ratio to

probability knowing a derisked with we exploratory SORAYA I'm -- success. was and not mirvetuximab's more confident analysis, about from especially so PARP perspective, prior impact And quite from remain use that that sharing activity. an also inhibitor technical data And prior results replicated that confident does will that even post-hoc given replicate MIRASOL my early already of has We MIRASOL from look and next knew high MIRASOL that year. the to forward data

hand the to conference like now would remarks. the closing over back for to I team

Great.

and year, we as we're to to with off and a So moving opening purpose. strong we're fast mentioned in remarks, the the start

company, top to to we of we're And execute at study, patients. line to potential launch, pipeline. excited our fully looking well so to on forward generating offer our good business our more point positioned as we PVAC a and pivotal the very advancing our and this to people, product data days transition our and the from ahead, We're integrated look our are first remainder

later data we'll look and we additional today, will our time where your month seeing programs. for thanks forward ASCO from all some to at So this you have Thanks.

This concludes today's conference participating. call. Thank you for

may disconnect. now You